Table 1.
Participant demographics and baseline characteristics
| Characteristic | Total (N = 11) |
|---|---|
| Female, n (%) | 9 (82) |
| Age (years) | |
| Mean (SD) | 54.8 (10.44) |
| Median (range) | 53 (39–68) |
| BMI (kg/m2), mean (SD) | 23.9 (3.09) |
| Height (cm), mean (SD) | 165.8 (8.42) |
| Weight (kg), mean (SD) | 65.5 (9.63) |
| Race, n (%) | |
| African American/African | 1 (9) |
| White/Caucasian/European | 10 (91) |
| CLE type, n (%) | |
| Chronic | 6 (55) |
| Acute | 0 |
| Subacute | 5 (45) |
| Concomitant medication a , n (%) b | |
| Any | 10 (91) |
| Hydroxychloroquine sulphate | 9 (82) |
| Prednisolone | 5 (45) |
| Cholecalciferol | 3 (27) |
| Metamizole sodium | 3 (27) |
Abbreviations: BMI, body mass index; CLE, chronic lupus erythematosus; SD, standard deviation.
Eligible participants were stable on either no treatment or treatment with: corticosteroids (≤7.5 mg/day prednisone or prednisone equivalent or less) for a minimum of 30 days prior to screening and through to Day 28; hydroxychloroquine (≤400 mg daily dose) for a minimum of 60 days prior to the randomization visit through to Day 28; topical steroids applied to areas of the body that are not exposed to GSK2646264 from screening to Day 28; topical calcineurin inhibitors and retinoids applied to areas of the body that are not exposed to GSK2646264 from screening to Day 28; opioids, if required for acute and chronic pain management.
Only medications being taken by three or more participants are shown.